Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.38
SPPI's Cash to Debt is ranked higher than
58% of the 1457 Companies
in the Global Biotechnology industry.

( Industry Median: 34.92 vs. SPPI: 1.38 )
SPPI' s 10-Year Cash to Debt Range
Min: 0.73   Max: 17918
Current: 1.38

0.73
17918
Equity to Asset 0.52
SPPI's Equity to Asset is ranked higher than
64% of the 1122 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. SPPI: 0.52 )
SPPI' s 10-Year Equity to Asset Range
Min: 0.2   Max: 0.94
Current: 0.52

0.2
0.94
F-Score: 4
Z-Score: 0.59
M-Score: -2.51
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -16.90
SPPI's Operating margin (%) is ranked higher than
80% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -91.29 vs. SPPI: -16.90 )
SPPI' s 10-Year Operating margin (%) Range
Min: -68658.54   Max: 30.17
Current: -16.9

-68658.54
30.17
Net-margin (%) -24.47
SPPI's Net-margin (%) is ranked higher than
78% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. SPPI: -24.47 )
SPPI' s 10-Year Net-margin (%) Range
Min: -67890.24   Max: 35.19
Current: -24.47

-67890.24
35.19
ROE (%) -17.26
SPPI's ROE (%) is ranked higher than
78% of the 1339 Companies
in the Global Biotechnology industry.

( Industry Median: -30.19 vs. SPPI: -17.26 )
SPPI' s 10-Year ROE (%) Range
Min: -888.98   Max: 39.19
Current: -17.26

-888.98
39.19
ROA (%) -9.34
SPPI's ROA (%) is ranked higher than
80% of the 1463 Companies
in the Global Biotechnology industry.

( Industry Median: -24.77 vs. SPPI: -9.34 )
SPPI' s 10-Year ROA (%) Range
Min: -321.68   Max: 23.98
Current: -9.34

-321.68
23.98
ROC (Joel Greenblatt) (%) -537.40
SPPI's ROC (Joel Greenblatt) (%) is ranked higher than
70% of the 1426 Companies
in the Global Biotechnology industry.

( Industry Median: -347.18 vs. SPPI: -537.40 )
SPPI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5547.35   Max: 3089.46
Current: -537.4

-5547.35
3089.46
Revenue Growth (3Y)(%) -4.60
SPPI's Revenue Growth (3Y)(%) is ranked higher than
73% of the 782 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. SPPI: -4.60 )
SPPI' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 211.9
Current: -4.6

0
211.9
» SPPI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

SPPI Guru Trades in Q1 2014

Jim Simons 171,307 sh (+146.42%)
Paul Tudor Jones Sold Out
» More
Q2 2014

SPPI Guru Trades in Q2 2014

Jim Simons 185,917 sh (+8.53%)
» More
Q3 2014

SPPI Guru Trades in Q3 2014

Jim Simons Sold Out
» More
Q4 2014

SPPI Guru Trades in Q4 2014

Jim Simons 248,000 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with SPPI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 20.70
SPPI's Forward P/E is ranked higher than
91% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SPPI: 20.70 )
N/A
P/B 1.55
SPPI's P/B is ranked higher than
93% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 6.95 vs. SPPI: 1.55 )
SPPI' s 10-Year P/B Range
Min: 0.63   Max: 5.23
Current: 1.55

0.63
5.23
P/S 2.08
SPPI's P/S is ranked higher than
94% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 37.39 vs. SPPI: 2.08 )
SPPI' s 10-Year P/S Range
Min: 1.07   Max: 650
Current: 2.08

1.07
650
EV-to-EBIT -11.13
SPPI's EV-to-EBIT is ranked higher than
67% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SPPI: -11.13 )
SPPI' s 10-Year EV-to-EBIT Range
Min: -26.9   Max: 63.5
Current: -11.13

-26.9
63.5
Current Ratio 2.03
SPPI's Current Ratio is ranked higher than
59% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. SPPI: 2.03 )
SPPI' s 10-Year Current Ratio Range
Min: 1.02   Max: 16.82
Current: 2.03

1.02
16.82
Quick Ratio 1.95
SPPI's Quick Ratio is ranked higher than
61% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: 4.12 vs. SPPI: 1.95 )
SPPI' s 10-Year Quick Ratio Range
Min: 1.02   Max: 16.8
Current: 1.95

1.02
16.8
Days Inventory 152.45
SPPI's Days Inventory is ranked higher than
85% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SPPI: 152.45 )
SPPI' s 10-Year Days Inventory Range
Min: 78.11   Max: 332.36
Current: 152.45

78.11
332.36
Days Sales Outstanding 138.24
SPPI's Days Sales Outstanding is ranked higher than
73% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 143.45 vs. SPPI: 138.24 )
SPPI' s 10-Year Days Sales Outstanding Range
Min: 9.09   Max: 4219.76
Current: 138.24

9.09
4219.76

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 100.00
SPPI's Price/Tangible Book is ranked lower than
63% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 10.60 vs. SPPI: 100.00 )
SPPI' s 10-Year Price/Tangible Book Range
Min: 0.66   Max: 814
Current: 100

0.66
814
Price/DCF (Projected) 1.09
SPPI's Price/DCF (Projected) is ranked higher than
99% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SPPI: 1.09 )
SPPI' s 10-Year Price/DCF (Projected) Range
Min: 1.26   Max: 9.32
Current: 1.09

1.26
9.32
Price/Median PS Value 0.48
SPPI's Price/Median PS Value is ranked higher than
96% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. SPPI: 0.48 )
SPPI' s 10-Year Price/Median PS Value Range
Min: 0.27   Max: 1505.68
Current: 0.48

0.27
1505.68
Earnings Yield (Greenblatt) -9.00
SPPI's Earnings Yield (Greenblatt) is ranked higher than
60% of the 1417 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. SPPI: -9.00 )
SPPI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.6   Max: 2183.8
Current: -9

1.6
2183.8

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NTR.Germany,
Spectrum Pharmaceuticals Inc was incorporated in Colorado in December 1987 as Americus Funding Corporation and reincorporated in Delaware in June 1997. The Company changed its corporate name in August 1996 to NeoTherapeutics, Inc., and to Spectrum Pharmaceuticals, Inc in December 2002. The Company and its wholly-owned subsidiaries is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology. The Company market four oncology drugs: FUSILEV injection, ZEVALIN injection, FOLOTYN injection, and MARQIBO injection. Its product portfolio consisting of both commercial stage and development stage products that address various cancer types. FUSILEV, a novel folate analog formulation and the pharmacologically active isomer (the levo-isomer) of the racemic compound, calcium leucovorin. FOLOTYN, a folate analogue metabolic inhibitor, was discovered by Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute and developed by Allos Therapeutics, Inc. ZEVALIN injection for intravenous use is a prescription medication that is part of a three step treatment regimen consisting of: two treatments of rituximab and one treatment of Yttrium-90 (Y-90) ZEVALIN. MARQIBO is a novel, sphingomyelin/cholesterol liposome-encapsulated formulation of the FDA-approved anticancer drug vincristine. The Company markets and sells its drugs through a direct sales force in the U.S., and through distributors in Europe and Japan. The Company competes with Astra Zeneca PLC, Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Co., Novartis AG, Genentech, Inc. (Roche), Bristol-Myers Squibb Company, GlaxoSmithKline, Biogen-IDEC Pharmaceuticals, Inc., OSI Pharmaceuticals, Inc. (Astellas Pharma), Cephalon, Inc. (Teva Pharmaceuticals), Sanofi-Aventis, Inc., Pfizer, Inc., Genta Incorporated, Merck, Celgene Corporation, BiPar Sciences, Inc., Genzyme Corporation, Shire Pharmaceuticals, Abbott Laboratories, Poniard Pharmaceuticals, Inc., and Johnson & Johnson. The development, production and marketing of its proprietary and generic drug and biologic products are subject to regulation for safety, efficacy and quality by numerous governmental authorities in the U.S. and other countries.
» More Articles for SPPI

Headlines

Articles On GuruFocus.com
http://seekingalpha. Aug 14 2012 
Spectrum: Allos Acquisition Means Huge Upside Potential May 04 2012 
5 Stocks Exceeding Expectations In 2012 Mar 31 2012 
Was Gilead's Acquisition of Pharmasset a Dose of Bad Medicine? Mar 05 2012 
Spectrum Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 10 2011 
Weekly CFO Buys Highlight: CNYD, PRWT, ANCB, SPPI, SPAX Jan 30 2011 
Weekly CFO Buys Highlight: FUL, SPPI, GRF, BPAX Jan 24 2011 
Weekly Top Insider Buys: NPBC, FUL, GAM, SHLM, SPPI Jan 23 2011 
Spectrum Pharmaceuticals Inc. (SPPI) CFO Brett L Scott buys 4,000 Shares Jan 21 2011 
Spectrum Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 04 2010 

More From Other Websites
10-K for Spectrum Pharmaceuticals, Inc. May 04 2015
Spectrum Pharmaceuticals Announces First Quarter 2015 Financial Results Teleconference and Webcast Apr 30 2015
Spectrum Pharmaceuticals Announces First Quarter 2015 Financial Results Teleconference and Webcast Apr 30 2015
The 52-Week Low Club for Wednesday Apr 08 2015
Spectrum Pharma May Be a Two-Blockbuster Stock Apr 03 2015
Coverage initiated on Spectrum Pharma by FBR Capital Apr 02 2015
Spectrum Pharmaceuticals Presents New Data on EVOMELATM (CE-Melphalan), at the Annual Meeting of the... Mar 30 2015
Spectrum Pharmaceuticals Presents New Data on EVOMELATM (CE-Melphalan), at the Annual Meeting of the... Mar 30 2015
SPECTRUM PHARMACEUTICALS INC Financials Mar 20 2015
SPECTRUM PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Mar 13 2015
Spectrum Pharma reports 4Q loss Mar 13 2015
Spectrum Pharma reports 4Q loss Mar 13 2015
Spectrum Pharmaceuticals Reports Robust Clinical Data and Strong 2014 Financial Results Mar 13 2015
Q4 2014 Spectrum Pharmaceuticals Inc Earnings Release - Time Not Supplied Mar 13 2015
Spectrum Pharmaceuticals Reports Robust Clinical Data and Strong 2014 Financial Results Mar 13 2015
Four Oncology Key Opinion Leaders to Present at Spectrum Pharmaceuticals' Analyst Day on Friday,... Mar 11 2015
Four Oncology Key Opinion Leaders to Present at Spectrum Pharmaceuticals’ Analyst Day on Friday,... Mar 11 2015
Spectrum Pharmaceuticals' CE-melphalan Under Review - Analyst Blog Mar 10 2015
Spectrum Pharmaceuticals Announces FDA's Acceptance of NDA Filing for Captisol-Enabled™ (Propylene... Mar 09 2015
Spectrum Pharmaceuticals Announces FDA's Acceptance of NDA Filing for Captisol-Enabled™ (Propylene... Mar 09 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK